News | July 26, 2023
The programme was conducted as a part of MPMCx, an exclusive management programme for MBBS doctors by IIM-Ahmedabad in collaboration with DailyRounds
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023
Farxiga is expected to have such a strong influence on the market due to the impressive results
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Subscribe To Our Newsletter & Stay Updated
